Should I Buy CELZ? CELZ 2026 Analysis

Should You Buy Creative Medical Technology Holdings Inc (CELZ) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

1.930

1 Day change

8.43%

52 Week Range

6.900

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: trend is technically bearish (SMA_200 > SMA_20 > SMA_5) and the statistical pattern outlook skews negative for the next week/month.
With no Intellectia buy signals, no news catalyst, and weak fundamentals (no revenue, ongoing losses), the risk/reward is unattractive for an impatient buyer looking for immediate upside.
Best stance is to avoid new entries here; only reconsider if price reclaims the pivot (~2.098) and holds above it with improving momentum.

Technical Analysis

Price context: pre-market ~2.00, which is below the pivot (2.098) and close to support S1 (1.949); this is a weak positioning unless it reclaims the pivot.
Trend: Bearish moving average stack (SMA_200 > SMA_20 > SMA_5) indicates the primary trend remains down.
Momentum: MACD histogram is positive (0.0145) but “positively contracting,” suggesting upside momentum is fading rather than strengthening.
RSI(6) ~42.2 (neutral-to-weak) shows no oversold bounce signal.
Key levels to watch: Support 1.949 then 1.857; Resistance 2.098 (pivot) then 2.247 and 2.339. A clean break above 2.098 is needed before a higher-probability long setup.
Pattern-based odds: ~60% chance of +1.09% next day, but -2.88% next week and -2.71% next month—near-term bounce risk exists, but broader bias is negative.

Positive Catalysts

- Potential for a short-term bounce if support at ~~1.95 holds and price quickly reclaims the pivot (~~2.10).
- Net loss improved YoY (net income less negative) in 2025/Q3, which is directionally positive even if still unprofitable.
- No notable insider/hedge fund selling pressure flagged in the provided trend snapshot (both neutral).

Neutral/Negative Catalysts

- No news in the last week: lack of event-driven catalyst reduces odds of an immediate upside re-rating.
- Bearish moving-average structure signals sellers still control the intermediate/longer trend.
- Fundamentals remain weak: revenue is still 0 and the company is loss-making; EPS worsened YoY.
- If price loses ~1.95 (S1), next support is ~1.86 (S2), implying downside room.
- Similar-pattern projection is negative for the next week/month, which conflicts with an “buy now” approach for an impatient timeframe.

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 0 (no growth base; still effectively no operating scale).
Net income: -1,235,934 (improved 18.82% YoY, but still materially negative).
EPS: -0.48 (down 36.00% YoY), indicating per-share profitability deteriorated.
Gross margin: reported negative (improved vs prior year per the snapshot), but still not indicative of a healthy core business model at this stage.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no observable recent Wall Street upgrade/downgrade trend to support a buy thesis.
Practical takeaway: without fresh analyst support or target raises, the setup relies mainly on technicals—which are currently bearish—and catalysts—which are absent.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Congress trading data

No recent congress trading data available.

Analyst Rating

Wall Street analysts forecast CELZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CELZ is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 1.780

Low

Averages

High

Current: 1.780

Low

Averages

High

Roth Capital

Jonathan Aschoff

Buy

downgrade

$26 -> $20

AI Analysis

2025-06-04

Reason